D

Dynavax Technologies Corp
D

DVAX

12.430
USD
-0.26
(-2.01%)
مغلق
حجم التداول
57,050
الربح لكل سهم
0
العائد الربحي
-
P/E
83
حجم السوق
1,633,980,193
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALT
    0.10000
    (1.46%)
    6.94000 USD
    B
    BCRX
    0.01500
    (0.20%)
    7.62000 USD
    E
    EBS
    0.650
    (6.37%)
    10.850 USD
    GSK
    GSK
    -0.340
    (-1.01%)
    33.440 USD
    I
    INO
    0.06500
    (2.96%)
    2.26000 USD
    MRNA
    MRNA
    2.600
    (7.24%)
    38.490 USD
    N
    NVAX
    0.02500
    (0.28%)
    8.84500 USD
    S
    SVA
    0
    (0.00%)
    0 USD
    TAK
    TAK
    -0.205
    (-1.56%)
    12.900 USD
    V
    VSTM
    0.12500
    (2.32%)
    5.51000 USD
    المزيد
الأخبار
المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.